medigraphic.com
Colegio de Medicina Interna de México.

2022, Number 4

<< Back Next >>

Med Int Mex 2022; 38 (4)

Replica: Antimicrobial use and abuse in COVID-19: When is its use justified?

Azañero-Haro J

Language: Spanish
References: 11
Page: 964-966
PDF size: 182.67 Kb.


Text Extraction

No abstract.


REFERENCES

  1. Pérez-Martínez CA, Padilla-Santamaría F, Helguera-León SA,Mejía-Cornejo JJ, Casados-Rodríguez BE, Martínez-AbarcaCI, et al. Uso y abuso de antimicrobianos en COVID-19:¿cuándo está justificado prescribir antibióticos? Med IntMéx 2021; 37 (6): 1015-29. https://doi.org/10.24245/mim.v37i6.4931

  2. Alós J-I. Resistencia bacteriana a los antibióticos: una crisisglobal. Enfermedades Infecc Microbiol Clin 2015; 33 (10):692-9. https://doi.org/10.1016/j.eimc.2014.10.004

  3. Langford BJ, So M, Raybardhan S, Leung V, Westwood D,MacFadden DR, et al. Bacterial co-infection and secondaryinfection in patients with COVID-19: a living rapid reviewand meta-analysis. Clin Microbiol Infect 2020; 26 (12):1622-9. https://doi.org/10.1016/j.cmi.2020.07.016.

  4. Monsó E. El microbioma respiratorio: más alla del cultivo.Arch Bronconeumol 2017; 53 (9): 473-4. https://doi.org/10.1016/j.arbres.2016.11.008

  5. Man WH, de Steenhuijsen Piters WAA, Bogaert D. The microbiotaof the respiratory tract: gatekeeper to respiratoryhealth. Nat Rev Microbiol 2017; 15 (5): 259-70. https://doi.org/10.1038/nrmicro.2017.14

  6. Martínez-Aguilar NE, Vargas-Camaño ME, Hernández-Pliego RR, Chaia-Semerena GM, Pérez-Chavira M delR, Martínez-Aguilar NE, et al. Inmunopatología de laenfermedad pulmonar obstructiva crónica. Rev AlergMéxico 2017; 64 (3): 327-46. https://doi.org/10.29262/ram.v64i3.263

  7. Zhu X, Ge Y, Wu T, Zhao K, Chen Y, Wu B, et al. Co-infectionwith respiratory pathogens among COVID-2019 cases.Virus Res 2020; 285: 198005. https://doi.org/10.1016/j.virusres.2020.198005.

  8. Soto A, Quiñones-Laveriano DM, Valdivia F, Juscamayta-López E, Azañero-Haro J, Chambi L, et al. Detection ofviral and bacterial respiratory pathogens identified bymolecular methods in COVID-19 hospitalized patients andits impact on mortality and unfavorable outcomes. InfectDrug Resist 2021; 14: 2795-807. https://doi.org/10.2147/IDR.S306439.

  9. Pérez-Lazo G, Soto-Febres F, Morales-Moreno A, Cabrera-Enríquez JA, Díaz-Agudo J, Rojas-Tovar R, et al. Uso racionalde antimicrobianos en tiempos de COVID-19 en Perú: rol delos programas de optimización del uso de antimicrobianose intervenciones desde el punto de vista de control deinfecciones. Horiz Méd Lima 2021; 21 (2).

  10. Chen X, Liao B, Cheng L, Peng X, Xu X, Li Y, et al. Themicrobial coinfection in COVID-19. Appl MicrobiolBiotechnol 2020; 1-9. https://doi.org/10.1007/s00253-020-10814-6.

  11. Garcia-Vidal C, Sanjuan G, Moreno-García E, Puerta-AlcaldeP, Garcia-Pouton N, Chumbita M, et al. Incidence of coinfectionsand superinfections in hospitalized patientswith COVID-19: a retrospective cohort study. Clin MicrobiolInfect 2021; 27 (1): 83-8. https://doi.org/10.1016/j.cmi.2020.07.041.




2020     |     www.medigraphic.com